Oral rigosertib: Phase I started

SymBio began an open-label, dose-escalation, Japanese Phase I trial to evaluate 280 and 560 mg oral rigosertib twice daily for the first 14 days of a 21-day cycle for about 6 cycles in MDS patients who failed, were intolerant to or progressed after treatment with chemotherapy during the past 4 weeks. SymBio said a pair of U.S. Phase II trials is evaluating oral rigosertib in front-line treatment for lower-risk MDS. ...